Timing considerations also matter
In the trials, different groups were assigned different target doses (1, 4, 8, or 12 mg), and the increase was paused or slowed if a person had side effects
Despite these numbers, GLP-1 drugs account for relatively small shares of total Medicaid spending and prescriptions, the report noted about 0.5% of all Medicaid prescriptions and 3.7% of gross Medicaid spending
It is noteworthy that none of the SGLT2 inhibitors have shown a significant reduction in developing acute ischaemic events myocardial infarction or stroke and, indeed, there is even the possibility of a signal of increased stroke risk in EMPA-REG OUTCOME
Tragen von Einmalhandschuhen
Hepatology 2017;67:123133